Company Overview of Celldex Therapeutics, Inc.
Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of various immunotherapy technologies and other cancer-targeting biologics. Its drug candidates include glembatumumab vedotin, an antibody-drug that is in Phase IIb study for the treatment of triple negative breast cancer and a Phase II study for the treatment of metastatic melanoma; Varlilumab, an immune modulating antibody that is in a Phase 1 study designed to enhance a patient's immune response against cancer; and CDX-3379, a human monoclonal antibody that is in Phase II study in combination with cetuximab for the treatment of head and neck squamous cell carcinoma. The company also d...
Perryville III Building
53 Frontage Road
Hampton, NJ 08827
Key Executives for Celldex Therapeutics, Inc.
Founder, President, CEO & Director
Total Annual Compensation: $859.4K
Founder, Chief Scientific Officer and Executive Vice President
Total Annual Compensation: $548.8K
Chief Product Development Officer and Senior Vice President
Total Annual Compensation: $419.0K
Compensation as of Fiscal Year 2016.
Celldex Therapeutics, Inc. Key Developments
Celldex Therapeutics, Inc. Announces Promising Early Data from Investigator-Initiated Pilot Study Evaluating the Combination of CDX-301 and Stereotactic Body Radiotherapy
Apr 20 18
Celldex Therapeutics, Inc. announced promising early data from an investigator-initiated pilot study evaluating the combination of CDX-301 and stereotactic body radiotherapy (SBRT) in patients with advanced non-small cell lung cancer (NSCLC). CDX 301 (recombinant human Flt3 ligand) is a potent hematopoietic cytokine that uniquely expands dendritic cells and hematopoietic stem cells. This translational study is the culmination of significant preclinical research into strategically combining radiation and immunotherapy to effectively treat aggressive tumors and is supported by a Small Business Innovation Research (SBIR) grant from the National Cancer Institute to Celldex in collaboration with Albert Einstein College of Medicine, part of Montefiore. The concept that increasing the number of dendritic cells with Flt3 ligand combined with an ablative course of radiation to the primary tumor induces a systemic anti-tumor response, suppresses metastases and promotes survival and immune memory was demonstrated through preclinical studies led by Dr. Chandan Guha and colleagues at the Einstein College of Medicine. 1 Based on this seminal work, a Phase 2 pilot study of CDX-301 in combination with SBRT was initiated at the Montefiore Einstein Center for Cancer Care. The study is currently enrolling up to 29 patients, and the primary objective is progression-free survival at four months after treatment (PFS4). Key secondary objectives include evaluation of dose-limiting toxicities and response rate in non-irradiated tumors, where tumor shrinkage from radiation therapy or CDX-301 independently would not be expected. Responses were particularly impressive when classified by PERCIST (PET Response in Solid Tumors) criteria, in which a partial response is at least a 45% reduction of total glycolytic activity, a volumetric measure of disease burden. The presentation included data from nine patients, seven of whom were previously treated with anti-PD(L)1 checkpoint inhibitors. The one-week course of treatment included subcutaneous injections of CDX-301 and SBRT directed to a single lung tumor lesion.
Celldex Therapeutics, Inc. - Special Call
Apr 16 18
To discuss topline METRIC results
Celldex Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Year Ended December 31, 2017
Mar 7 18
Celldex Therapeutics, Inc. reported earnings results for the fourth quarter and year ended December 31, 2017. For the quarter, the company reported total revenue of $3.5 million in the fourth quarter of 2017 compared to $1.9 million a year ago. The increase in revenue was primarily due to the manufacturing service agreements with the International AIDS Vaccine Initiative and Frontier Biotechnologies, Inc. Net loss was $3.8 million or $0.03 per share for the fourth quarter of 2017 compared to a net loss of $32.3 million, or $0.30 per share for the comparable periods in 2016
For the year, the company reported total revenue of $12.7 million compared to $6.8 million for the comparable periods in 2016. Net loss was $93.0 million or $0.72 per share for the year ended December 31, 2017 compared to a $128.5 million, or $1.27 per share for the comparable periods in 2016.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|